{
  "docId": "019de075-e64c-773b-a5bd-08e51f7033a7",
  "docSlug": "8122e3ca3ef658190e4851ff70e19f61",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 25 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 25,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 120,
  "notes": "Data presented at EASL 2022. Shows longitudinal patient data for patients 42, 43, and 48.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e64c-773b-a5bd-08e51f7033a7/15",
  "deckHref": "/decks/019de075-e64c-773b-a5bd-08e51f7033a7",
  "deckJsonHref": "/decks/019de075-e64c-773b-a5bd-08e51f7033a7.json",
  "deckAnchorHref": "/decks/019de075-e64c-773b-a5bd-08e51f7033a7#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.75,
        "x": 0.04,
        "y": 0.65
      },
      "kind": "chart",
      "text": "Exhausted vs Effector T-cell frequency charts",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f466f3e9-4fbd-4774-8368-23ad131ac22f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.75,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Longitudinal patient data charts (Patients 42, 43, 48)",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5030da14-e4de-41cb-90e5-1e9d5e5d975d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.23,
        "x": 0.75,
        "y": 0.5
      },
      "kind": "list",
      "text": "Upregulation of HBV-specific T-cell activation markers observed in all 7 patients assessed to date. Two profiles of HBV-specific T cell IFN-y responses observed. Elevation between Wk 16-28 which coincides with nadir of HBsAg reduction. *Elevation after imdusiran dosing completed, between Wk 48-60",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a2cd2ecf-a653-48a3-96e2-89505b3371f9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.9,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "AB-729-001: Treatment with Imdusiran Reactivates HBV Specific Immunity in Some Patients",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a749d15d-4286-4e45-817b-bd59aab627b6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 15,
      "from": 10,
      "beatId": "d2e1c560-c296-4472-968d-b63e27e07b30",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "Imdusiran RNAi Therapeutic, Robust HBsAg declines, Imdusiran demonstrates robust and sustained HBsAg declines",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}